Liver Cancer: Cabozantinib can safely and effectively treat compensated advanced liver cancer!

Hepatocellular carcinoma (HCC) is the most common malignant primary liver cancer and the third leading cause of cancer-related deaths affecting more than 500,000 patients each year
.

Most advanced HCC has lost the chance of cure, and systemic treatment is often used

The multi-kinase inhibitor Cabozantinib (Cabozantinib) has been approved for hepatocellular carcinoma that has previously been treated with sorafenib

11 medical centers in Austria, Switzerland, and Germany retrospectively screened HCC patients treated with cabozantinib, and analyzed the characteristics of the patients, the occurrence of adverse events, the duration of treatment, and overall survival (OS)
.

Screening

A total of 88 patients were enrolled
.

47 patients had underlying liver disease, of which 26 (30%) had NAFLD/NASH, and 21 (24%) had hepatitis C infection

Infection 41 (47%) were treated as second-line therapy Cabozantinib, 46 (52%) using Cabozantinib or later as a third-line therapy, 41 (47%) were treated as second-line therapy Cabozantinib, 46 (52%) used cabozantinib as third-line or later therapy

OS and PFS of the total queue

OS and PFS of the total queue

As of April 1, 2020, 6 (7%) patients had achieved partial remission, 28 (32%) patients remained stable, and 28 (32%) patients had progressed
.

Fifty-two (59%) patients died during follow-up

Treatment of OS in patients with different responses

Treatment of OS in patients with different responses

In the entire cohort, the median OS after treatment with cabozantinib was 7.
0 months, the median OS for Child-Pugh A patients was 9.
7 months, and the median OS for Child-Pugh B patients was only 3.
4 Month
.

The median OS of 37 patients (42%) who combined the CELESTIAL inclusion and exclusion criteria was 11.

In the entire cohort, the median OS after treatment with cabozantinib was 7.

Survival rate of patients with different Child-Pugh grades

Survival rate of patients with different Child-Pugh grades

The most common adverse events were fatigue and diarrhea (15.

In summary, cabozantinib can effectively treat advanced HCC with compensated liver cirrhosis, and has good safety

Cabozantinib can effectively treat advanced HCC with compensated liver cirrhosis and has good safety.

Original source:

Finkelmeier Fabian, Scheiner Bernhard, Leyh Catherine et al.

Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort in this message